I think I will take the advice of some of the professionals in the industry regarding the potential for the device. While I do agree at some stage in the US we will need to conduct a RCT but I think the results from the RCT will be consistent with what they have been getting in the smaller PanCo study.
Dr Zarni Win, Consultant Radiologist and Nuclear Medicine Physician at The London Clinic, said: “I am particularly excited about this new therapy, as it now offers a much higher chance for pancreatic cancer patients with locally advanced disease to undergo curative surgery following OncoSil therapy, compared to a more pessimistic outcome with conventional treatment.”
OSL Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)